Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States

References

• NIH National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER) stat fact sheets: Chronic Myeloid Leukemia (CML) [Internet]. 2016. http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed June 6, 2016
   Google Scholar
• Kurzrock R, Kantarjian HM, Druker BJ, et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-30
   PubMed Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-30
   PubMed Web of Science ®Google Scholar
• Mace ML, Dahl J, Jabbour EJ. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert Opin Pharmacother 2015;16:999-1007
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015;15:323-34
   PubMed Web of Science ®Google Scholar
• Giles FJ, Rosti G, Beris P, et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Rev Hematol 2010;3:665-73
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O’Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
   PubMed Web of Science ®Google Scholar
• Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010;3:47
   PubMed Web of Science ®Google Scholar
• Firwana B, Sonbol MB, Diab M, et al. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Int J Cancer 2016;138:1545-53
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Ayyagari R, Reichmann WM, et al. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev 2014;40:285-92
   PubMed Web of Science ®Google Scholar
• Nilotinib Product Label. United States Food and Drug Administration (FDA). 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf. Accessed November 2, 2015
   Google Scholar
• Dasatinib Product Label. United States Food and Drug Administration (FDA). 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf. Accessed November 2, 2015
   Google Scholar
• Red Book - Wholesale Aquisition Costs (WAC) [Internet]. Truven Health Analytics Micromedex Solutions. 2016. http://micromedex.com/products/product-suites/clinical-knowledge/redbook. Accessed June 7, 2016
   Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Consumer Price Index (CPI). United States Department of Labor, Bureau of Labor Statistics. 2016. http://www.bls.gov/cpi/. Accessed June 15, 2016
   Google Scholar
• Bagdonavicius V, Nikulin M. On goodness‐of‐fit for homogeneity and proportional hazard. Appl Stochastic Models Busi Ind 2006;22:607-19
   Web of Science ®Google Scholar
• Gronnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 1996;2:315-28
   PubMedGoogle Scholar
• Stock JH, Watson MW. Introduction to econometrics. 2nd ed. Boston: Pearson/Addison Wesley; 2007. xlii, 796 p.
   Google Scholar
• Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. In: York SN, editor. Breakthroughs in Statistics; New York, NY: Springer, 1992. p 11-28
   Google Scholar
• Hosmer DW, Lemesbow S. Goodness of fit tests for the multiple logistic regression model. Commun Stat Theory Meth 1980;9:1043-69
   Web of Science ®Google Scholar
• Darkow T, Kadlubek PJ, Shah H, et al. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. J Occup Environ Med 2007;49:22-30
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin 2011;27:1263-71
   PubMed Web of Science ®Google Scholar
• Guerin A, Revol C, Ramanakumar AV, et al. Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP). 56th ASH Annual Meeting and Exposition. December 6, 2014. San Francisco, CA. https://ash.confex.com/ash/2014/webprogram/Paper69591.html. Accessed April 1, 2016
   Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984;63:789-99
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-8
   PubMed Web of Science ®Google Scholar